In the Jan-Mar 2013 quarter, GSK Pharma's revenues increased 1.5% YoY to Rs.6321mn as against our expectations of Rs 6850mn, Karvy Stockbroking said in a review note post the first quarter results.

GlaxoSmithKline Pharmaceuticals today reported a 37.52% rise in its net profit to Rs 169.01 crore for the first quarter ended March 31, 2013 from the same period previous fiscal.

GlaxoSmithKline Pharmaceuticals is trading higher by 6% to Rs 2,460 after reporting 37% year-on-year (yoy) growth in net profit at Rs 169 crore for the quarter ended March 31, 2013 (Q1).

GlaxoSmithKline Pharmaceuticals (GSK Pharma) delivered December 2012 quarter results largely in line with expectations. The company grew its sales at a healthy 16% driven by new product launches across product categories.

GlaxoSmithKline Pharmaceuticals today reported a 1.29 per cent rise in its net profit at Rs 138.51 crore for the quarter ended December 31, 2012.The company had posted a net profit of Rs 136.74 crore for the corresponding period previous fiscal, the

Global drug major GlaxoSmithKline (GSK) and Hyderabad-based Biological E will set up a joint venture (JV) to develop a six-in-one vaccine for polio and other infectious diseases.

India is not the only market where the London-headquartered GlaxoSmithKline (GSK) Plc has said that it would increase its stakeholding. The British major has also said that it would take up its ownership to 80 per cent in its Nigerian consumer business.

GlaxoSmithKline Plc plans to buy up to an additional 31.8% stake in its Indian consumer products arm for about 52.2 billion rupees ($940 million), as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health

GlaxoSmithKline Pharmaceuticals today reported 4.44% rise in net profit at Rs 152.34 crore for the quarter ended September 30, 2012 on back of robust sales.

Drug firm GlaxoSmithKline Pharmaceuticals today reported a 10.83% increase in net profit to Rs 163.52 crore for the quarter ended June 30, 2012, on robust growth across all business verticals.

Drug firm GlaxoSmithKline Pharmaceuticals today reported a 10.83% increase in net profit to Rs 163.52 crore for the quarter ended June 30, 2012, on robust growth across all business verticals.

GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the US biotech firm for three months, sources familiar with the situation said on Sunday.

GlaxoSmithKline is to take its unsolicited $2.6 billion takeover bid for Human Genome Sciences direct to shareholders in the US biotech group by launching a tender offer at $13 a share this week.

GlaxoSmithKline Pharmaceuticals today said its net profit rose by 18.18% to Rs 136.74 crore for the quarter ended December 31, 2011, over the same period last fiscal due to growth in its specialty products and vaccines.

Intense competition leading to pricing pressure is hurting the company’s revenue growth and profitability.

Dragged down by lower growth of anti-infectives segment and rise in employee cost, GlaxoSmithKline (GSK) Pharmaceuticals today reported 7.57% decline in net profit for the third quarter ended September 30, 2011 to Rs 145.86 crore over the same period last

The company had posted a net profit of Rs 128.99 crore in the same period previous fiscal, it said in a filing to the Bombay Stock Exchange (BSE).

Multinational (MNC) pharmaceutical companies have rallied on the bourses, with many of them trading at lifetime highs in an otherwise weak market.

GlaxoSmithKline Pharmaceuticals (GSK) Limited has further strengthened its presence in the oncology space in India with the launch two drugs — Revolade and Votrient.

GlaxoSmithkline Pharmaceuticals today posted a massive decline in its net profit at Rs 46 lakh in the quarter ended March 31, from Rs 161 crore recorded in the corresponding period in the previous year.